DUBLIN--(BUSINESS WIRE)--
      ICON
      plc, (NASDAQ:ICLR) a global provider of drug development
      solutions and services to the pharmaceutical, biotechnology and medical
      device industries, today announced the appointment of Dr. Steve Cutler
      to the ICON Board of Directors.
    
    
      Dr. Cutler joined ICON in 2011 as Group President, ICON Clinical
      Research Services. Dr. Cutler successfully led this business to
      significant growth and, as a result, was promoted to Chief Operating
      Officer in January 2014. As Chief Operating Officer, Dr. Cutler has
      responsibility for all of ICON's operational service areas, including
      clinical research, early phase, laboratories, DOCS resourcing and
      commercialisation and outcomes. Dr. Cutler's operational leadership as
      Chief Operating Officer has helped ICON successfully deliver innovative
      and integrated services and solutions to customers.
    
    
      Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle.
      Prior to Kendle, Dr. Cutler held various senior roles in both Quintiles
      and Sandoz (now Novartis). Dr. Cutler holds a B.Sc. and a Ph.D from the
      University of Sydney and a Masters of Business Administration from the
      University of Birmingham (UK).
    
    
      "Since joining ICON in 2011, Dr. Cutler has made a significant
      contribution to ICON and our journey towards becoming the trusted
      partner in drug development," commented Mr. Thomas Lynch, Chairman
      of ICON. "I am delighted to now welcome Dr. Cutler to the ICON Board
      and I look forward to his continued success with and contribution to
      ICON."
    
    
      About ICON plc
    
    
      ICON plc is a global provider of drug development solutions and services
      to the pharmaceutical, biotechnology and medical device industries. The
      company specialises in the strategic development, management and
      analysis of programs that support clinical development - from compound
      selection to Phase I-IV clinical studies. With headquarters in Dublin,
      Ireland, ICON currently, operates from 77 locations in 38 countries and
      has approximately 11,700 employees.
    
    
      Further information is available at www.iconplc.com.
    
    
      This press release contains forward-looking statements. These
      statements are based on management's current expectations and
      information currently available, including current economic and industry
      conditions. These statements are not guarantees of future performance or
      actual results, and actual results, developments and business decisions
      may differ from those stated in this press release. The forward-looking
      statements are subject to future events, risks, uncertainties and other
      factors that could cause actual results to differ materially from those
      projected in the statements, including, but not limited to, the ability
      to enter into new contracts, maintain client relationships, manage the
      opening of new offices and offering of new services, the integration of
      new business mergers and acquisitions, as well as economic and global
      market conditions and other risks and uncertainties detailed from time
      to time in SEC reports filed by ICON, all of which are difficult to
      predict and some of which are beyond our control. For these reasons, you
      should not place undue reliance on these forward-looking statements when
      making investment decisions. The word "expected" and variations of such
      words and similar expressions are intended to identify forward-looking
      statements. Forward-looking statements are only as of the date they are
      made and we do not undertake any obligation to update publicly any
      forward-looking statement, either as a result of new information, future
      events or otherwise. More information about the risks and uncertainties
      relating to these forward-looking statements may be found in SEC reports
      filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
      available on the SEC's website at http://www.sec.gov.
    
    
      ICON/ICLR-F
    
  
View source version on businesswire.com: http://www.businesswire.com/news/home/20151125005161/en/
    
      ICON plc
Investor Relations, 1-888-381-7923
or
Brendan
      Brennan, + 353 -1-291-2000
Chief Financial Officer
or
Simon
      Holmes, + 353 -1-291-2000
EVP Investor Relations and Corporate
      Development
    
Source: ICON plc
News Provided by Acquire Media